open access

Vol 3, No 4 (2014)
Review articles (submitted)
Published online: 2014-09-22
Get Citation

Pioglitazone for the treatment of type 2 diabetes

Katarzyna Nabrdalik, Edyta Cichocka, Joanna Żywiec, Artur Chodkowski, Janusz Gumprecht
Diabetologia Kliniczna 2014;3(4):176-180.

open access

Vol 3, No 4 (2014)
Review articles (submitted)
Published online: 2014-09-22

Abstract

Pioglitazon is available on polish market since November 2013 after registration and admission to trading in July 2012. This medicine is a thiazolidinedione belonging to a group of drugs called insulin sensitizers. Pioglitazon may be started as monotherapy oradded as a second or third drug in patients who did not meet the therapy goals even though treated with metformin or metformin combined with other oral antidiabetic drugs or incretinomimetics as well as it can be added to insulin therapy. Pioglitazon is though to have a good influence of cardiovascular risk factors that is why it lowers cardiovascular risk as well as it has renoprotective properties. Pioglitazon’s side effects can be avoided when prescribed with caution.

Abstract

Pioglitazon is available on polish market since November 2013 after registration and admission to trading in July 2012. This medicine is a thiazolidinedione belonging to a group of drugs called insulin sensitizers. Pioglitazon may be started as monotherapy oradded as a second or third drug in patients who did not meet the therapy goals even though treated with metformin or metformin combined with other oral antidiabetic drugs or incretinomimetics as well as it can be added to insulin therapy. Pioglitazon is though to have a good influence of cardiovascular risk factors that is why it lowers cardiovascular risk as well as it has renoprotective properties. Pioglitazon’s side effects can be avoided when prescribed with caution.
Get Citation

Keywords

pioglitazone, cardiovascular risk, renoprotection

About this article
Title

Pioglitazone for the treatment of type 2 diabetes

Journal

Clinical Diabetology

Issue

Vol 3, No 4 (2014)

Pages

176-180

Published online

2014-09-22

Bibliographic record

Diabetologia Kliniczna 2014;3(4):176-180.

Keywords

pioglitazone
cardiovascular risk
renoprotection

Authors

Katarzyna Nabrdalik
Edyta Cichocka
Joanna Żywiec
Artur Chodkowski
Janusz Gumprecht

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl